Cytochrome P450 in living donor liver transplantation

King-Wah Chiu*, Toshiaki Nakano, Kuang-Den Chen, Li-Wen Hsu, Chia-Yun Lai, Ching-Yin Huang, Yu-Fan Cheng, Shigeru Goto and Chao-Long Chen

Abstract
Cytochrome P450 metabolizes many drugs in the liver. Three genotypes of CYP2C19 with extensive, intermediate, and poor metabolizing activity, respectively, have been identified in peripheral blood of transplant recipients and new liver grafts in living donor liver transplantation (LDLT). The expression of the final genotype in liver graft biopsies depends on the donor, whereas the expression in peripheral blood mononuclear cells depends on the recipient. The metabolizing isoenzyme of the major anti-rejection agents passes through CYP3A4, CYP3A5 and MDR1, which have also been identified to have similar biological characteristics as genotype of CYP2C19 in liver tissue. Recently, pyrosequencing has been used to investigate the expressions of different genotypes in liver grafts in LDLT. This review focuses on recent findings regarding the biological expressions of the CYP2C19, CYP3A4, CYP3A5 and MDR1 genotypes in liver grafts before and after LDLT. The application of pyrosequencing may be beneficial in further research on liver transplantation. Laser capture microdissection of hepatocytes in liver grafts may be a direction for future research.

Keywords:
Cytochrome P450, CYP2C19, CYP3A4, CYP3A5, MDR1, Living donor liver transplantation, Pyrosequencing, Homogenous phenomenon

Core tip
The genotypic expressions of CYP2C19, CYP3A4, CYP3A5 and MDR1 contribute to the mainstream by donor liver grafts in living donor liver transplantation. Pyrosequencing can identify homogenous phenomenon when different genotype expressions are found between the donor and recipient. These findings can help transplant hepatologists and those in the field of organ transplantation to understand how drug metabolism modifies cytochrome P450 in a new graft after liver transplantation.

Introduction
Cytochrome P450 contain isoenzymes which metabolize many drugs in the liver [1]. To understand this complicated system, CYP2C19 and its genotypes can be used to describe the characteristics of the isoenzymes in cytochrome P450. CYP2C19 is one of the important isoenzymes responsible for drug metabolism including anti-convulsant and antacid agents [2, 3]. Based on the metabolic rate of a drug, there are three genotypes including extensive metabolizer (homozygous extensive metabolizer, HomEM), intermediate metabolizer (heterozygous extensive metabolizer, HetEM) and poor metabolizer (PM). The distribution of each differs depending on ethnicity. We previously identified that PM accounts for about 13.3 to 16.7 % of cases in Taiwan [4, 5]. In liver transplant recipients with the PM CYP2C19 genotype, lower doses of proton-pump inhibitors can be used to avoid drug intoxication in the treatment of peptic ulcer disease [6]. However, changes in the genotype in recipients and donors such as HomEM to PM or PM to HetEM in the setting of living donor liver transplantation (LDLT) have yet to be elucidated. This review focuses on our recent reports to investigate the isoenzymes that are modified by cytochrome P450 after LDLT.

* Correspondence: c471026@ms6.hinet.net
Liver transplantation program, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, College of Medicine, 123 Ta-Pei Road, Niao-Sung District, Kaohsiung 833, Taiwan

© 2015 Chiu et al; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
CYP2C19
CYP2C19 is one of the polymorphic isoenzymes in the cytochrome P450 system that is responsible for the metabolism of several therapeutically important drugs such as proton-pump inhibitors including omeprazole, lansoprazole and pantoprazole [7]. Because of the impact on drug metabolism, CYP2C19 may be important in LDLT. We previously used DNA extraction and polymerase chain reaction (PCR) to amplify DNA with all six fragments of the CYP2C19 gene corresponding to exon 1 (406 bp), 2–3 (606 bp), 4 (271 bp), 5 (409 bp), 7 (325 bp), and 9 (529 bp). Genomic DNA was isolated from the peripheral blood mononuclear cells of donors and recipients, and the CYP2C19 polymorphisms were identified. HomEM had wild-type alleles (*1/*1), HetEM had one mutated allele (*1/*2 or *1/*3), and PM had homozygous mutations (m1 in exon 5 or m2 in exon 4) of CYP2C19 (*2/*2, *3/*3 or *2/*3). Although the genotypes of CYP2C19 were different between the donors and recipients before LDLT, the original genotype expressions in the peripheral blood of the recipients did not affect the CYP2C19 genotypes of the donor liver grafts with different allelic patterns after LDLT [4].

In fact, the liver enzymes were easily detected early after LDLT, and the one of the important concerns was acute rejection. The incidence of acute rejection was 12.9–15.0 % in our earlier reports [5, 8]. When elevated liver enzymes are noted within 1 month after liver transplantation and the ratio of aspartate transaminase/alanine transaminase (AST/ALT) is less than 1.0, it should be considered an episode of acute rejection [8]. Many interesting findings have been reported when the genotypes of CYP2C19 have been applied to abnormal liver enzymes after LDLT. For example, the incidence of abnormal liver enzymes has been reported to be higher with CYP2C19 genotype HomEM (84.2 %) than HetEM (51.5 %) and PM (16.7 %), with a linear trend relationship [5]. Logistic regression analysis showed that the higher risk estimate of abnormal liver enzymes with HomEM was 26.7 times that of PM (16.7 %), with a linear trend relationship [5]. Logistic regression analysis showed that the higher risk estimate of abnormal liver enzymes with HomEM was 26.7 times that of PM (16.7 %), with a linear trend relationship [5].

Percutaneous liver biopsies are performed when clinically required after LDLT. The polymorphisms of CYP2C19 found in liver tissue depends on the liver graft of the donor, even if the genotype is different between the recipient and donor. Western blotting can be used to identify the genotype, however the reason for the discrepancies between extensive and poor metabolizers in CYP2C19 after LDLT have yet to be explained [9]. In our previous study, direct sequencing of CYP2C19 genotypes showed that the sequence of graft liver CYP2C19 at exon 5 (681G > A) expressed a mixed pattern but was finally similar to that of the donor after LDLT. We named this morphological change the homogenous phenomenon [10] as shown in Fig. 1. Although the peripheral blood continuously flows through the liver graft, the effect on genotype expression from the recipient was limited. In DNA sequencing, the final presentation of CYP2C19 polymorphisms of the liver graft fully expressed the genotyping characteristic arising from the donor with limited morphological changes. In a donor with the CYP2C19 genotype PM (m1 in exon 5, 681A, *2/*2) and a recipient with HetEM (681 A/G, *1/*2) LDLT, follow-up liver biopsies showed a mixed pattern of CYP2C19 sequencing with a similar wave pattern but smaller amplitude than that of the donor [10]. It is known that the major anti-rejection agents such as cyclosporine A and tacrolimus are metabolized through cytochrome P450 with isoenzymes CYP3A4, CYP3A5 and multiple drug resistant 1 (MDR1), however CYP2C19 may not be involved with those agents. Therefore, we performed further research on CYP3A4, CYP3A5 and MDR1.

CYP3A5
CYP3A5 is one of the most important isoenzymes for the metabolism of anti-rejection agents in cytochrome P450. Different from CYP2C19, CYP3A5 does not have any other genotypes. The morphological pattern did not present a significant quantitative expression in direct DNA sequencing or Western blotting. Investigations of CYP3A5*3 haplotypes with A/A, A/G and G/G genotypes may lead to a better understanding of the possible homogenous phenomenon in LDLT. We used PCR assays with the forward primer 5’-CATGACCTTAGTAGACA-GATGAC-3’ and reverse primer 3’-GGTCCAAACAGG-GAAGAAATA-3’, and PCR with restriction fragment length polymorphism (PCR-RFLP) to explore the positions of CYP3A5 polymorphisms at rs776746 and identified the haplotypes of a single nucleotide polymorphism (SNP). The CYP3A5 *1/*1 genotype showed bands of 148, 125 and 20 bp in length, and the CYP3A5 *3/*3 genotype showed bands of 168 and 125 bp in length [11].

Pyrosequencing was performed with PyroMark Assay Design Software 2.0, and PCR assays were prepared with a PyroMark PCR Kit (Qiagen). The biotinylated forward primer 5’-TGTTACCCAGGTGTTAACA-3’ and a reverse primer at the 5’ end (5’-GGTCCAAACAGG-GAAGAAAT-3’) were applied. The biotinylated PCR products were analyzed and expressed with proportional haplotyping of CYP3A5*3 from the peripheral blood and liver graft biopsy tissue of the recipients who underwent LDLT [11]. This method allowed for the objective investigation of the proportions of A/A, A/G and G/G and comparisons before and after LDLT on...
changes in cytochrome P450. RFLP was also performed to document the products belonging to A/G or G/G when an unusual interpretation was noted in pyrosequencing. According to pyrosequencing of the CYP3A5*3 genotypes, the homogenous phenomenon could be identified in the liver graft of the recipient after LDLT. This suggests that the final expression of CYP3A5*3 in liver grafts is truly dependent on the donor with only a limited change in the recipient. This biogenetic effect could potentially be predicted before LDLT in the screening stage of liver donation.

**CYP3A4**

Similar to the CYP3A family, CYP3A4*18 could be easily identified with PCR-RFLP for DNA sequencing as with CYP3A5*3. A different primer for the PCR assay was used with a forward primer 5′-CACCTGATGTCAGCAGAATCT-3′ and reverse primer 5′-AATAGAAAGCAGATGAAACCAGCC-3′. The probe was prepared with 5′-TTTTTTTTTTTTTTTTTTTTTTTTTACCTCCTTCCTTCCATGTAC-3′ for CYP3A4*18-G and 5′-TTTTTTTTTTTTTTTTTTTTTTTTTACCTCCTCCCTCCTTCCATGTAC-3′ for CYP3A4*18-A [12]. Based on the haplotypes of the SNP from PCR-RFLP, three polymorphism genotypes were expressed as T/T, T/C and C/C by CYP3A4*18. CYP3A4 is an important isoenzyme in cytochrome P450 in liver and renal transplantation. Particular attention to the role of CYP3A4 when using anti-fungal agents such as ketoconazole concomitantly with anti-rejection drugs such as tacrolimus should be paid as this can cause severe pharmacokinetic drug to drug interactions [13–15]. In the CYP3A4*18 genotyping pyrosequence of the liver graft biopsies, the homogenous phenomenon was identified with the CYP3A4*18 SNP with the wild-type T allele and mutant variant C allele of the liver grafts, which arose from the donor and was different from the peripheral blood of the recipient after LDLT. The clinical implication is that recipients may be need a high dose of tacrolimus due to the extensive metabolism of the potential donor expressing CYP2C19 and CYP3A4*18 exon 10 wild-type 878 T > C/T after liver transplantation.

**MDR1**

Transporter proteins (MDR1, gene coding glycoprotein-P, P-gp, ABCB1 gene) impact the required dose of anti-rejection organ transplantation agents such as tacrolimus and cyclosporine A due to pharmacokinetics. MDR1-3435 is a common polymorphism involved in both the pharmacokinetics and pharmacodynamics in LDLT. We used PCR-RFLP to explore genotype exon 26 C3435T variant alleles in MDR1, and PCR assays using the forward primer 5′-TGCTGTCCTGAAGTTGATCTGA-3′ and reverse primer 5′-ACATTAGGCAGTGAAGATGTCG-3′. The PCR product was digested with Sau3A I. In the pyrosequencing expression of the SNP, the C allele was the wild-type, and the T allele was the mutant variant of MDR1-3435. The homogenous phenomenon was also identified in the difference between the liver graft and the peripheral blood of the recipients in C > C/T, C/T > C, C/T > T and T > C/T, but was similar to those of the donors.

![Image](image-url)
after LDLT [16]. The genetic polymorphisms of the drug-metabolizing enzymes was found to be different from the donor, and a homogenous phenomenon was identified. However, changes in isoenzyme polymorphisms in the liver grafts were not manifested in the peripheral blood. Therefore, to understand the correlation of genes in liver grafts after liver transplantation when liver graft biopsy tissue is available from the recipient, the drug concentration in the blood is important, however examinations of the donor blood can further reveal the association between the liver graft and recipient after LDLT. It is difficult to know whether anti-rejection agent metabolism occurs through the isoenzymes of the liver graft, or whether it is related to intestinal isoenzymes. Small expressions of intestinal isoenzymes have been reported [17–19]. In our recent report, we investigated the relationship between CYP2C19 and CYP3A4*18, CYP3A5*3, and MDR1-3435. None of the haplotypes of these isoenzymes had a significant difference on the proportional distribution [16]. In other studies, liver graft hepatocytes were isolated using laser capture microdissection [20–22]. Interestingly, two different genotypes of isoenzymes were identified in the cytochrome P450 system, one arising from the donor liver and the other originating from the recipient’s circulating blood. The drugs passing through the common polymorphism may impact both the pharmacokinetics and pharmacodynamics. Finally, acute rejection usually occurs within one month after liver transplantation, and the homogenous phenomenon may play a role in the slowdown of acute rejection after LDLT. Our findings also suggest that intestinal isoenzymes play a compensatory role within one month after liver transplantation [13, 23]. With time, the coordinator role of the different genotypes creates a homogenous phenomenon to adjust the anti-rejection agents. Therefore, acute rejection should be resolution about one month after LDLT [24, 25].

In other words, CYP2C19 is one of the common isoenzymes of cytochrome P450 in the field of the gastroenterology for the proton pump inhibitor metabolism. The characteristic of different metabolism is believable treatment guide line by the gastroenterologists in clinical practice. In our recent reports, the genotypes of CYP2C19 could be modified by the donor graft not only on the drug metabolism for the peptic ulcer, but also possible on the immunosuppression agent causing abnormal liver function at the first month after LDLT. It may be play a major role to the monitoring of the drug metabolism in immunosuppression effect. We step-by-step to study more and more isoenzymes related to the field of the liver transplantation and discovery the evidence of homogenous phenomenon similarly take place on the CYP3A4, CYP3A5 and MDR-1. This information should be benefit on the pharmacologic and organ transplantation worldwide.

**Conclusion**

In the cytochrome P450 system, isoenzyme polymorphisms may play an important role in drug metabolism, primarily in donor liver grafts with different genotypes after liver transplantation. Genomic polymorphisms may be mutant with a biogenetic phenomenon, and the mainstream expression depends on the donor in the cytochrome P450 system. Pyrosequencing may be a reliable method to identify changes in polymorphisms after LDLT.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

KWC TN carried out the molecular genetic studies, participated in the sequence alignment and drafted the manuscript. CYH carried out the immunocassays. CYL LWH participated in the sequence alignment. KWC TN KDC participated in the design of the study and performed the statistical analysis. SG conceived of the study, and YFC CLC participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

**Acknowledgments**

This work was appreciatively assisted by Ms. Mei-Chin Hsu for the statistical analysis, and partially supported by grant number CMRPG8B0921 from the Chang Gung Memorial Hospital of Taiwan.

**Funding**

This work was supported by a grant from the Chang Gung Memorial Hospital (CMRPBG631 to KWC) of Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Received:** 27 March 2015 **Accepted:** 30 April 2015

**Published online:** 15 May 2015

**References**

1. Berno G, Zaccarelli M, Gori C, Tempestilli M, Pucci L, Antinori A, et al. Potential implications of CYP3A4, CYP3A5 and MDR-1 genetic variants on the efficacy of Lopinavir/Ritonavir (LPV/r) monotherapy in HIV-1 patients. J Int AIDS Soc. 2014;17(4 Suppl 3):19589. doi:10.7448/jias.17.4.19589. PMID: 25394094; PMCID: PMC4224892.

2. Sahara S, Sugimoto M, Uotani T, Ichikawa H, Yamade M, Iwaiuzumi M, et al. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole. Aliment Pharmacol Ther. 2013;38(9):1129–37. doi:10.1111/apt.12492. PMID: 24099474.

3. Sugimoto M, Sihai N, Nishino M, Kodai C, Uotani T, Sahara S, et al. Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese. Eur J Clin Pharmacol. 2014;70(9):1073–8. doi:10.1007/s00228-014-1713-y. PMID: 24963880.

4. Chiu KW, Tai WC, Nakano T, Tseng HP, Cheng YF, Jawan B, et al. Donor Graft does not Affect P450 2C19 Genotype Expressed on Peripheral Blood in Recipient with Living Donor Liver Transplantation. Clinical Transplant. 2010;24(6):830–4. doi:10.1111/j.1399-0012.2010.01220.x. PMID: 20263133.

5. Chiu KW, Nakano T, Hu TH, Tseng HP, Cheng YF, Jawan B, et al. CYP2C19 genotypes and graft pathology in recipients after liver transplantation. Ann Transpl. 2010;15(4):38–43. PMID: 21183874.

6. Kóbori L, Köhalmy K, Porrog P, Sáváry E, Gézer Z, Fazakas J, et al. Drug-induced liver graft toxicity caused by cytochrome P450 poor metabolism. Br J Clin Pharmacol. 2008;65(3):428–36. PMID: 18070218; PMCID: PMC2291242.

7. Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013;19(1):25–35. doi:10.5056/jnm.2013.19.1.25. PMID: 23350044.

8. Chiu KW, Chen YS, de Villa VH, Wang CC, Eng HL, Wang SH, et al. Characterization of liver enzymes on living related liver transplantation patients with acute rejection. Hepato-Gastroenterol. 2005;52(66):1825–17. PMID:16394785.
9. Chiu KW, Nakano T, Tseng HP, Cheng YF, Jawan B, Eng HL, et al. CYP2C19 activity of liver tissues in western blot analysis on living donor liver transplantation. Hepatogastroenterology. 2012;59(115):805–8. doi:10.5754/hge.097922. PMID: 22469723.

10. Chiu KW, Nakano T, Hu TH, Tseng HP, Cheng YF, Jawan B, et al. Homogenous phenomenon of graft liver CYP2C19 genotypes after living donor liver transplantation. Eur J Clin Invest. 2012;42(4):302–6. doi:10.1111/j.1365-2362.2011.02589.x. PMID: 21913914.

11. Chiu KW, Nakano T, Chen KD, Lai CY, Hsu LW, Chiu HC, et al. Pyrosequencing to identify homogeneous phenomenon when using recipients/donors with different CYP3A5*3 genotypes in living donor liver transplantation. PLoS One. 2013;8(8):e71314. doi:10.1371/journal.pone.0071314. PMID: 23951129.

12. Chiu KW, Nakano T, Chen KD, Hsu LW, Lai CY, Chiu HC, et al. Homogeneous phenomenon of the graft when using different genotype characteristic of recipients/donors in living donor liver transplantation. World J Hepatol. 2013;5(11):642–8. doi:10.4254/wjh.v5.i11.642. PMID: 24303093; PMCID: PMC3847948.

13. Uesugi M, Kikuchi M, Shinke H, Omura T, Yonezawa A, Matsubara K, et al. Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantation. Pharmacogenet Genomics. 2014;24(7):356–66. doi:10.1097/FPC.000000000000060. PMID: 24911663.

14. Khan E, Killackey M, Kumbala D, LaGuardia H, Liu YJ, Qin HZ, et al. Long-term outcome of ketoconazole and tacrolimus co-administration in kidney transplant patients. World J Nephrol. 2014;3(3):107–13. doi:10.5527/wjnr.v3.i3.107. PMID: 25332902; PMCID: PMC4202487.

15. Lecoffe C, Eloy P, Chauvin B, Wyplosz B, Amilien V, Massias L, et al. Worsening pneumonitis due to a pharmacokinetic drug-drug interaction between everolimus and voriconazole in a renal transplant patient. J Clin Pharm Ther. 2014. doi:10.1111/jcpt.12234. PMID: 25417855.

16. Chiu KW, Hu TH, Nakano T, Chen KD, Lai CY, Hsu LW, et al. Biological interaction of CYP2C19 genotypes with CYP3A4*18, CYP3A5*3, and MDR1-3435 in living donor liver transplantation. Transplant Res. 2013;2(1). doi:10.1186/2047-1440-2-6. PMID: 23617933.

17. Ma B, Wang J, Sun J, Li M, Xu H, Sun G, et al. Permeability of rhynchophylline across human intestinal cell in vitro. Int J Clin Exp Pathol. 2014;7(5):1957–66 [PMID: 24966905; PMCID: PMC4069913].

18. Chen YK, Han LZ, Xue F, Chen CH, Lü J, Yang TH, et al. Personalized tacrolimus dose requirement by CYP3A5 but not ABCB1 or ACE genotyping in both recipient and donor after pediatric liver transplantation. PLoS One. 2014;9(10):e109464. doi:10.1371/journal.pone.0109464. PMID: 25310192; PMCID: PMC4195667.

19. Tsukimoto M, Ohashi R, Torimoto N, Togo Y, Suzuki T, Maeda T, et al. Effects of the inhibition of intestinal P-glycoprotein on aliskiren pharmacokinetics in cynomolgus monkeys. Biopharm Drug Dispos. 2014. doi:10.1007/s10521-014-9976-5. PMID: 25264342.

20. Mustafa A, Cenayko C, Mitry RR, Quaglia A. Laser microdissection microscopy: application to cell culture. Methods Mol Biol. 2012;806:385–92. doi:10.1007/978-1-61779-367-7_25. PMID: 22057465.

21. Aini W, Miyagawa-Hayashino A, Ozeki M, Tsujiyama T, Tamaki K, Uemoto S, et al. Frequent hepatocyte chimerism in long-term human liver allografts independent of graft outcome. Transpl Immunol. 2013;28(2–3):100–5. doi:10.1016/j.trim.2012.12.002. PMID: 23268137.

22. Kandathil AJ, Graw F, Quinn J, Hwang HS, Torbenson M, Perelson AS, et al. Use of laser capture microdissection to map hepatitis C virus-positive hepatocytes in human liver. Gastroenterology. 2013;145(6):1404–10. doi:10.1053/j.gastro.2013.08.034. PMID: 23973767; PMCID: PMC4005338.

23. Uesugi M, Hosokawa M, Shinke H, Hashimoto T, Kawai T, et al. Influence of cytochrome P450 (CYP) 3A4*1G polymorphism on the pharmacokinetics of tacrolimus, probability of acute cellular rejection, and mRNA expression level of CYP3A5 rather than CYP3A4 in living-donor liver transplant patients. Biol Pharm Bull. 2013;36(11):1814–21. PMID: 24189425.

24. Gómez-Braña MA, Salcedo M, Fondevila C, Suarez F, Castellote J, Rufian S, et al. Impact of donor and recipient CYP3A5 and ABCB1 genetic polymorphisms on tacrolimus dosage requirements and rejection in Caucasian Spanish liver transplant patients. J Clin Pharmacol. 2013;53(1):1146–54. doi:10.1002/jcph.154. PMID: 23900887.

25. Wollard JB, Rerolle JP, Picard N, Rousseau A, Guillaudeau A, Munteau E, et al. Donor P-gp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients on cyclosporine therapy in a long-term follow-up. Clin Pharmacol Ther. 2010;88(1):95–100. doi:10.1038/clpt.2010.62. PMID: 20505666.